Gilead’s Quad Makes It Through FDA Panel Review Despite Renal Safety Concerns
Executive Summary
Antiviral Drugs Advisory Committee votes 13-1 in favor of the four-drug-in-one HIV treatment. Panel members offer a host of suggestions for post-marketing studies, including determining the best means for detecting Quad-related renal injury early.
You may also be interested in...
It’s Not Just Dosing: Stribild’s Side Effect Profile Could Give It An Edge In HIV Market
Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
Renal Safety In The Spotlight At FDA Panel Review Of Gilead’s Quad
The four-drug, single-tablet HIV treatment regimen was associated with higher rates of serious adverse events and study drug discontinuations due to renal events in the pivotal trials. FDA is seeking the Antiviral Drugs Advisory Committee’s views on renal safety and whether monitoring recommendations should be stricter than those proposed by Gilead.